[1]
|
Lee, S., Kang, T., Song, K., et al. (2021) Effect of Microvascular Invasion Risk on Early Recurrence of Hepatocellular Carcinoma after Surgery and Radiofrequency Ablation. Annals of Surgery, 273, 564-571. https://doi.org/10.1097/SLA.0000000000003268
|
[2]
|
Endo, Y., Alaimo, L., Lima, H., et al. (2023) A Novel Online Calculator to Predict Risk of Microvascular Invasion in the Preoperative Setting for Hepatocellular Carcinoma Patients Undergoing Curative-Intent Surgery. Annals of Surgical Oncology, 30, 725-733. https://doi.org/10.1245/s10434-022-12494-0
|
[3]
|
Kloeckner, R., Galle, P. and Bruix, J. (2021) Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology, 73, 137-149. https://doi.org/10.1002/hep.31424
|
[4]
|
Xie, D.-Y., Ren, Z.-G., Fan, J., Gao, Q. and Zhou, J. (2020) 2019 Chinese Clinical Guidelines for the Management of Hepatocellular Carcinoma: Updates and Insights. HepatoBiliary Surgery and Nutrition, 9, 452-463. https://doi.org/10.21037/hbsn-20-480
|
[5]
|
Portolani, N., Coniglio, A., Ghidoni, S., et al. (2006) Early and Late Recurrence after Liver Resection for Hepatocellular Carcinoma: Prognostic and Therapeutic Implications. Annals of Surgery, 243, 229-235. https://doi.org/10.1097/01.sla.0000197706.21803.a1
|
[6]
|
Yamamoto, Y., Ikoma, H., Morimura, R., et al. (2015) Optimal Duration of the Early and Late Recurrence of Hepatocellular Carcinoma after Hepatectomy. World Journal of Gastroenterology, 21, 1207-1215. https://doi.org/10.3748/wjg.v21.i4.1207
|
[7]
|
Tabrizian, P., Jibara, G., Shrager, B., et al. (2015) Recurrence of Hepatocellular Cancer after Resection: Patterns, Treatments, and Prognosis. Annals of Surgery, 261, 947-955. https://doi.org/10.1097/SLA.0000000000000710
|
[8]
|
Villanueva, A. (2019) Hepatocellular Carcinoma. The New England Journal of Medicine, 380, 1450-1462. https://doi.org/10.1056/NEJMra1713263
|
[9]
|
Chan, A.W.H., Zhong, J.H., Berhane, S., et al. (2018) Development of Pre and Post-Operative Models to Predict Early Recurrence of Hepatocellular Carcinoma after Surgical Resection. Journal of Hepatology, 69, 1284-1293. https://doi.org/10.1016/j.jhep.2018.08.027
|
[10]
|
Fu, X., Yang, Y. and Zhang, D. (2022) Molecular Mechanism of Albumin in Suppressing Invasion and Metastasis of Hepatocellular Carcinoma. Liver International, 42, 696-709. https://doi.org/10.1111/liv.15115
|
[11]
|
Fattovich, G., Stroffolini, T., Donato, F. and Zagni, I. (2004) Hepatocellular Carcinoma in Cirrhosis: Incidence and Risk Factors. Gastroenterology, 127, S35-S50. https://doi.org/10.1053/j.gastro.2004.09.014
|
[12]
|
Moon, A.M., Singal, A.G. and Tapper, E.B. (2020) Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clinical Gastroenterology and Hepatology, 18, 2650-2666. https://doi.org/10.1016/j.cgh.2019.07.060
|
[13]
|
Mazzaferro, V., Llovet, J., Miceli, R., et al. (2009) Predicting Survival after Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Retrospective, Exploratory Analysis. The Lancet Oncology, 10, 35-43. https://doi.org/10.1016/S0084-3873(09)79540-9
|
[14]
|
Pawlik, T.M., Delman, K.A., Vauthey, J.-N., et al. (2005) Tumor Size Predicts Vascular Invasion and Histologic Grade: Implications for Selection Of Surgical Treatment for Hepatocellular Carcinoma. Liver Transplantation, 11, 1086-1092. https://doi.org/10.1002/lt.20472
|
[15]
|
Onaca, N., Davis, G.L., Jennings, L.W., et al. (2009) Improved Results of Transplantation for Hepatocellular Carcinoma: A Report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transplantation, 15, 574-580. https://doi.org/10.1002/lt.21738
|
[16]
|
Sheng, X., Ji, Y., Ren, G.-P., Lu, C.-L., Yun, J.-P., Chen, L.-H., et al. (2020) A Standardized Pathological Proposal for Evaluating Microvascular Invasion of Hepatocellular Carcinoma: A Multicenter Study by LCPGC. Hepatology International, 14, 1034-1047. https://doi.org/10.1007/s12072-020-10111-4
|
[17]
|
Isik, B., Gonultas, F., Sahin, T. and Yilmaz, S. (2020) Microvascular Venous Invasion in Hepatocellular Carcinoma: Why Do Recurrences Occur? Journal of Gastrointestinal Cancer, 51, 1133-1136. https://doi.org/10.1007/s12029-020-00487-9
|
[18]
|
Wickham, S., West, M.B., Cook, P.F. and Hanigan, M.H. (2011) Gamma-Glutamyl Compounds: Substrate Specificity of Gamma-Glutamyl Transpeptidase Enzymes. Analytical Biochemistry, 414, 208-214. https://doi.org/10.1016/j.ab.2011.03.026
|
[19]
|
Bachhawat, A.K. and Kaur, A. (2017) Glutathione Degradation. Antioxidants & Redox Signaling, 27, 1200-1216. https://doi.org/10.1089/ars.2017.7136
|
[20]
|
Bai, C., Zhang, M., Zhang, Y., He, Y., Dou, H., Wang, Z., et al. (2022) Gamma-Glutamyltransferase Activity (GGT) Is a Long-Sought Biomarker of Redox Status in Blood Circulation: A Retrospective Clinical Study of 44 Types of Human Diseases. Oxidative Medicine and Cellular Longevity, 2022, Article ID: 8494076. https://doi.org/10.1155/2022/8494076
|
[21]
|
Corti, A., Belcastro, E., Dominici, S., Maellaro, E. and Pompella, A. (2020) The Dark Side of Gamma-Glutamyltransferase (GGT): Pathogenic Effects of an ‘Antioxidant’ Enzyme. Free Radical Biology & Medicine, 160, 807-819. https://doi.org/10.1016/j.freeradbiomed.2020.09.005
|
[22]
|
Wong, L., Bozhilov, K., Hernandez, B., Kwee, S., Chan, O., Ellis, L., et al. (2019) Underlying Liver Disease and Advanced Stage Liver Cancer Are Associated with Elevated Neutrophil-Lymphocyte Ratio. Clinical and Molecular Hepatology, 25, 305-316. https://doi.org/10.3350/cmh.2019.0004
|
[23]
|
Geh, D., Leslie, J., Rumney, R., Reeves, H.L., Bird, T.G. and Mann, D.A. (2022) Neutrophils as Potential Therapeutic Targets in Hepatocellular Carcinoma. Nature Reviews Gastroenterology & Hepatology, 19, 257-273. https://doi.org/10.1038/s41575-021-00568-5
|
[24]
|
Ader, I., Brizuela, L., Bouquerel, P., Malavaud, B. and Cuvillier, O. (2008) Sphingosine Kinase 1: A New Modulator of Hypoxia Inducible Factor 1alpha during Hypoxia in Human Cancer Cells. Cancer Research, 68, 8635-8642. https://doi.org/10.1158/0008-5472.CAN-08-0917
|